Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 63629-9326

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63629-9326). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
A line graph depicting clinical response measured as 'ADAS-cog Change from Baseline (Mean ± SE)' over 30 weeks of drug treatment. It compares Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups, showing trends in clinical improvement or decline during the treatment period.*
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
A line graph showing the cumulative percentage of patients versus the ADCS-ADL change from baseline, comparing Donepezil Hydrochloride 10 mg/day to placebo. The x-axis represents changes from baseline in ADCS-ADL scores, and the y-axis represents the cumulative percentage of patients. Two curves depict patient outcomes for the two groups.*
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
A line graph showing SIB change from baseline (LS mean ± SE) over 24 weeks of drug treatment for Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The graph indicates clinical improvement above baseline and clinical decline below, with the 23 mg/day dose showing greater improvement than the 10 mg/day dose across time points.*
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
A cumulative percentage of patients chart depicting SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis shows SIB change ranging from positive to negative values, while the y-axis shows the cumulative percentage of patients from 0 to 100%. Two curves represent the different dosage groups.*
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
A bar chart comparing the percentage of patients with different clinical outcomes rated by CIBIC-plus for Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The categories shown on the horizontal axis are Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with corresponding patient percentages on the vertical axis.*
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
A cumulative percentage of patients graph showing change from baseline on the x-axis and cumulative percentage on the y-axis. It compares placebo, donepezil hydrochloride 5 mg, and donepezil hydrochloride 10 mg groups, illustrating patient response measured by changes in ADAS-cog scores, with a small table summarizing treatment group percentages at score changes of -7, -4, and 0.*
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
Bar graph showing the distribution of CIBIC-plus ratings as percentages of patients in three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo. The categories range from Markedly Improved to Markedly Worse on the horizontal axis.*
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
A line graph showing the ADAS-cog mean change from baseline (±SE) over 15 weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The graph illustrates clinical improvement with donepezil groups versus clinical decline with placebo over the treatment period.*
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
A cumulative percentage of patients plot depicting changes from baseline in the ADAS-cog score for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis shows change from baseline values, and the y-axis shows the cumulative percentage of patients. The graph highlights points of 7 and 4 changes and no change, with a table summarizing proportions of patients at different change thresholds for each treatment group.*
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
A bar chart showing the percentage of patients by CIBIC-plus rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Categories range from markedly improved to markedly worse, illustrating patient response distribution across these treatments.*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
A line graph showing SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment. Two lines represent Donepezil Hydrochloride 10 mg/day and Placebo. The y-axis shows mean change from baseline with standard error bars, while the x-axis represents months of treatment. The graph includes annotations for clinical improvement, baseline, and clinical decline.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
A cumulative percentage curve graph comparing SIB change from baseline between Donepezil Hydrochloride 10 mg/day and placebo. The x-axis shows SIB change from baseline with negative values, while the y-axis represents the cumulative percentage of patients, ranging from 0 to 100%. The graph depicts two lines: a solid line for Donepezil Hydrochloride and an open square line for placebo.*
FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
A line graph comparing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment between Donepezil Hydrochloride 10 mg/day and placebo groups. The x-axis represents months of treatment (0, 3, 6), and the y-axis shows mean change from baseline with an indication of clinical improvement or decline. Donepezil shows less decline compared to placebo.*
FDA Label Image

Chemical Structure (Donepezil Str)

Chemical Structure (Donepezil Str)
Chemical structure of Donepezil Hydrochloride showing the arrangement of its molecular components including the methoxy groups, piperidine ring, and phenyl group with the hydrochloride salt indicated.*
FDA Label Image

Label (Lbl636299326)

Label (Lbl636299326)
Donepezil Hydrochloride Tablets USP 5 mg film-coated tablets label showing dosage strength and quantity of 90 tablets. The label indicates Bryant Ranch Prepack as the repackager and Aurobindo Pharma Limited as the manufacturer. It includes storage instructions and two QR codes, one for the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.